Biosimilars & Innovator Biologics

Join us for 2 full days of in-depth discussions on the law governing biosimilars and innovator biologics.

As the number of FDA-approved biosimilar products continues to grow, the need for a solid guiding framework becomes more critical than ever before. While the stakeholders wait for finality on the rules governing significant matters like interchangeability, substitution and equivalency, it is clear that biosimilars will remain a top priority for the FDA.

The biosimilars market continues to maintain momentum as we head into 2021, but questions remain as to whether the U.S. market will catch up with Europe and whether biosimilars will provide their intended cost-savings.

Join the “who’s who” of the biosimilars and innovator biologics industries as they gather for ACI’s 2021 Summit on Biosimilars & Innovator Biologics, and contemplate these and other probing questions.

• Learn, analyze and benchmark with key In-House and Industry stakeholders including AAM, BIO & PhRMA
• Hear directly from critical Government Agencies like FDA, FTC and USPTO on current and future initiatives
• Benefit from Content that Stands Out: No stale sessions – no fluff. The agenda has been redesigned to address cutting edge concerns under the guidance of ACI’s Biosimilars & Innovator Biologics Advisory Board Members
• Recreate the connections and networking opportunities you would have at an onsite event on our captivating and interactive virtual platform, making distance irrelevant!
• PLUS! Earn Diversity and Ethics CLE Credits
  

Prepare to enter the next decade of this revolutionary law.

Biologics have become the fastest-growing class of therapeutic compounds. They have provided innovative treatment alternatives for people who suffer from some of the most serious medical conditions known to man. The incorporation of biosimilar products into the U.S. marketplace was designed to improve patient access and decrease healthcare costs. While much has evolved since the enactment of the BPCIA, the traditional barriers remain.

Now, more than ever, strategies to overcome these barriers are essential to improve the understanding of biosimilar products in the United States. The need for a solid guiding framework becomes more critical than ever before.

The next decade will see more litigation in this sphere. Further, and to an increasing extent, IPR proceedings challenging patents protecting biologic medicines, including IPRs filed before any action was taken under the BPCIA. Finally, the future will usher in considerable changes growing the scope of products that are regulated and litigated under the BPCIA.

Join the “who’s who” of the biosimilars and innovator biologics industries as they gather virtually to discuss and contemplate the impact of these critical developments.